- Hims & Hers Health Inc
- 09 March 2026 12:54:19
Source: Sharecast
Shares of Hims & Hers rocketed in pre-market trade on Monday as it announced the news, which is part of a new strategy for weight loss care treatments involving GLP-1s.
In the US, Hims & Hers now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale.
The company said that by aligning its domestic and international models in weight loss, it will become "the largest global consumer health platform for access to more affordable, approved medications".
It noted that the US weight loss landscape has transformed dramatically since it entered the market in 2023.
"Progress in the industry has made a broader range of FDA-approved GLP-1 treatments available at more affordable prices, with more flexible dosing options and greater diversity of form factors, accelerating customer demand for branded, FDA-approved medications," it said.
As a part of this shift, Hims will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers.
Hims has entered into an agreement with Novo Nordisk that will bring Ozempic® (semaglutide) 0.5 mg, 1 mg, and 2 mg injections and Wegovy® (semaglutide) pills and injections to the platform later this month, including 1.7 mg or 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets.
"Over the coming months, Hims & Hers will educate US weight loss customers on their options across an expanded assortment of FDA-approved treatments, and when providers determine it to be clinically appropriate, support a seamless transition to these medications," it said. "In the future, Hims & Hers and Novo Nordisk hope to collaborate to bring other products to market as they become available, further increasing the range of innovative treatments from which providers can choose on the platform."
Last month, Hims said it had abandoned plans to sell its own version of the Wegovy weight-loss drug. However, Novo Nordisk said at the time that it was still planning to file a lawsuit against Hims for infringing on its patents.
At 1250 GMT, Hims shares were up 51% in pre-market trade at $23.70, while Novo shares were 1.7% higher at DKK252.05.